The Obesity and Fat Metabolism in HIV-infected Individuals workshop took place at the National Institutes of Health in Rockville, MD on May 22 and 23, 2018. 

Materials

     Agenda

Presentations 

Welcome and Opening Remarks

Griffin Rodgers, Director, National Institute of Diabetes and Digestive and Kidney Diseases

Catherine Godfrey, National Institute of Allergy and Infectious Diseases

Andrew Bremer, National Institute of Diabetes and Digestive and Kidney Diseases

Session I: Overview- Setting the Stage

 

Chair: Peter Hunt, University of California, San Franscisco

Session Overview:

• Brown vs beige fat: generalized obesity vs dysfunctional adipose tissue
• lifespan issues

• Overview of the underlying biology of immune system activation linking it to obesity

          Clovis Palmer, Burnet Institute

• Epigenetic link - in utero issues

         Mary-Elizabeth Patti, Joslin Diabetes Center

• Fat types, distribution, sex differences, age differences, racial and ethnic differences

          Aaron Cypess, National Institute of Diabetes and Digestive and Kidney Diseases

Session II: It's the Virus!

Co-Chairs: Todd Brown, Johns Hopkins University

Roger Paredes, IrsiCaixa AIDS Research Institute

Session Overview:

• Relationship between HIV and its viral products and fat 

• HIV viral products and the immunometabolism

          Dorothy Lewis, The University of Texas Health Science Center at Houston

• miRNA, dicer and adipose tissue in HIV: novel pathways of fat regulation and organ specific cross-talk in HIV

          Steve Grinspoon, Massachusetts General Hospital

• Fat and HIV persistence, role of fat metabolism and inflammation

           Marta Giralt, University of Barcelona

Session III: Immune and Metabolic Interactions

Co-Chairs: Steve Grinspoon, Massachusetts General Hospital

Jason Baker, University of Minnesota

Session Overview:

• What WBCs are in fat? (M1, M2, Tregs, T effectors, NK cells, innate immune lymphocytes, and possibly even B-cells)
• the adipocyte as a monocyte origin cell
• Adipose tissue function, dysfunction, and fat fibrosis. What does this all mean?

            Suneil Koliwad, University of California San Francisco

• Fat as an immunologically active tissue: Defining the scope and cell types

           Alyssa Hasty, Vanderbilt University School of Medicine

• Role of leptin and other adipokines in HIV infection and HIV-related obesity

          John Koethe, Vanderbilt University

Session IV: GI Tract and Adipocyte Interactions

Co-Chairs: Rohit Loomba, University of California, San Diego

Netanya Utay, University of Texas Houston

Session Overview: 

• The interplay between HIV and the GI tract, adipose tissue, and the liver
• Other microbial "players" involved in mediating interactions between HIV and tissues

• GI tract barrier breakdown and adipocyte inflammation

          Janet Lo, Massachusetts General Hospital

• Microbiome and products of microbial metabolism

          Ivan Vujkovic -Cvijin, National Institute of Allergy and Infectious Diseases

• Liver disease/fatty liver, function of total fat, dysfunctional adipose tissue, and a depot that can't handle it.... Difference between HIV and non-HIV 

          Colleen Hadigan, National Institute of Allergy and Infectious Diseases

 

Session V: Pharmacology and Treatment of Obesity

Chair: Jordan Lake, University of Texas Health Science Center

Session Overview:

• Non-viral effects of current HIV therapy 
• Viral and non-viral considerations for future HIV therapies

• ART effect on fat quantity and quality

           Grace McComsey, University Hospitals Health System and Case Western Reserve University

• Metformin

          Alex Soukas, Center for Genomic Medicine

• Other treatment options in the pipeline

          Steven Heymsfield, Pennington Biomedical Research Center

Session VI: How do we translate this information to the clinic? What clinical trials are needed? What tools are needed?

Co-Chairs: Judith Currier, University of California, Los Angeles

                  Grace Aldrovandi, University of California, Los Angeles

Session Overview:

• Moving the science forward
• What clinical trials are needed?
• What tools are needed?

• Measuring endpoints and outcomes

Caroline Apovian, Boston University School of Medicine

• What clinical trials are needed?

Turner Overton, University of Alabama School of Medicine

 

This workshop was sponsored by:

National Institute of Allergy and Infectious Diseases

National Institute of Diabetes and Digestive and Kidney Diseases

National Institues of Health Office of AIDS Research

National Instiutes of Health Office of Research on Women's Health